全文获取类型
收费全文 | 265篇 |
免费 | 47篇 |
国内免费 | 43篇 |
专业分类
化学 | 286篇 |
力学 | 3篇 |
综合类 | 1篇 |
数学 | 7篇 |
物理学 | 58篇 |
出版年
2023年 | 7篇 |
2022年 | 23篇 |
2021年 | 33篇 |
2020年 | 23篇 |
2019年 | 20篇 |
2018年 | 18篇 |
2017年 | 11篇 |
2016年 | 24篇 |
2015年 | 17篇 |
2014年 | 19篇 |
2013年 | 31篇 |
2012年 | 25篇 |
2011年 | 15篇 |
2010年 | 9篇 |
2009年 | 8篇 |
2008年 | 13篇 |
2007年 | 14篇 |
2006年 | 5篇 |
2005年 | 11篇 |
2004年 | 4篇 |
2003年 | 3篇 |
2002年 | 6篇 |
2001年 | 2篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 1篇 |
排序方式: 共有355条查询结果,搜索用时 15 毫秒
51.
Chemical Design of Nuclear‐Targeting Mesoporous Silica Nanoparticles for Intra‐nuclear Drug Delivery
《中国化学》2018,36(6):481-486
Targeted drug delivery has been widely explored for efficient tumor therapy with desired efficacy but minimized side effects. It is widely known that large numbers of DNA‐toxins, such as doxorubicin, genes, reactive oxygen species, serving as therapeutic agents, can result in maximized therapeutic effects via the interaction directly with DNA helix. So after cellular uptake, these agents should be further delivered into cell nuclei to play their essential roles in damaging the DNA helix in cancer cells. Here, we demonstrate the first paradigm established in our laboratory in developing nuclear‐targeted drug delivery systems (DDSs) based on MSNs for enhanced therapeutic efficiency in the hope of speeding their translation into the clinics. Firstly, nuclear‐targeting DDSs based on MSNs, capable of intranuclear accumulation and drug release therein, were designed and constructed for the first time, resulting in much enhanced anticancer effects both in vitro and in vivo. Such an MSNs‐based and nuclear‐targeted drug/agent delivery strategy was further applied to overcome multidrug resistance (MDR) of malignant tumors, intra‐nuclearly deliver therapeutic genes, photosensitizers, radio‐enhancement agents and photothermal agents to realize efficient gene therapy, photodynamic therapy, radiation therapy and photothermal therapy, respectively. 相似文献
52.
Kazuma Shimoda Takahiro Mitsuoka Kenta Ueda Hiroshi Suemune Go Hirai Mariko Aso 《Tetrahedron letters》2018,59(51):4528-4531
A dendritic bisphosphonate carrying three bisphosphonate (BP) units in close proximity was designed as a ligand to conjugate large therapeutic molecules for their bone selective delivery. The Bu3P-catalyzed conjugate addition of nitromethane to vinylidene bisphosphonate was effective to construct a quaternary carbon center carrying BP units. Owing to multivalent interactions, the dendritic bisphosphonate showed considerable affinity for the bone mineral hydroxyapatite even in the presence of a competitor, demonstrating potential as a bone targeting ligand. 相似文献
53.
Viktor Reshetnikov Steffen Daum Dr. Christina Janko Weronika Karawacka Dr. Rainer Tietze Prof. Dr. Christoph Alexiou Dr. Solomiya Paryzhak Dr. Tetiana Dumych Prof. Dr. Rostyslav Bilyy Dr. Philipp Tripal Dr. Benjamin Schmid Dr. Ralf Palmisano Prof. Dr. Andriy Mokhir 《Angewandte Chemie (International ed. in English)》2018,57(37):11943-11946
Mitochondrial membrane potential is more negative in cancer cells than in normal cells, allowing cancer targeting by delocalized lipophilic cations (DLCs). However, as the difference is rather small, these drugs affect also normal cells. Now a concept of pro‐DLCs is proposed based on an N‐alkylaminoferrocene structure. These prodrugs are activated by the reaction with reactive oxygen species (ROS) forming ferrocenium‐based DLCs. Since ROS are overproduced in cancer, the high‐efficiency cancer‐cell‐specific targeting of mitochondria could be achieved as demonstrated by fluorescence microscopy in combination with two fluorogenic pro‐DLCs in vitro and in vivo. We prepared a conjugate of another pro‐DLC with a clinically approved drug carboplatin and confirmed that its accumulation in mitochondria was higher than that of the free drug. This was reflected in the substantially higher anticancer effect of the conjugate. 相似文献
54.
本文采用活性亚结构拼接原理,设计并合成了15个新型含哌啶的查尔酮类衍生物,利用1H NMR、13C NMR和HR-MS对结构进行表征,并初步评价了其抗宫颈癌和抗顺铂耐药宫颈癌活性作用。结果表明,化合物6g具有一定的抗肿瘤活性和逆转顺铂耐药作用;并采用Elisa法、联合顺铂用药、Western Blot和分子对接对化合物6g与VEGFR-2和P-gp靶点进行了初步的研究。本研究为基于VEGFR-2和P-gp双靶点新型分子靶向查尔酮类衍生物的设计提供了一条思路。 相似文献
55.
以D-半乳糖和二缩三乙二醇为原料,经乙酰化、糖基化和叠氮化钠取代等反应合成了带叠氮连接臂的半乳糖配基,通过点击化学反应将其与炔丙基修饰的马蹄金素(MTS)衍生物进行连接,设计合成了6个具有潜在肝靶向性的半乳糖糖基化MTS衍生物.通过1H NMR,13C NMR,1H-1H COSY,HMQC,DEPT和ESI-MS对其结构进行了表征;采用Hep G2 2.2.15细胞模型初步评价了目标化合物的抗乙型肝炎病毒(HBV)活性.结果表明,所有目标化合物对HBV DNA的复制均有抑制作用,且具有一定的量效关系;化合物15f在50μg/m L浓度下对Hep G2 2.2.15细胞株的抑制率为83%,具有进一步研究的价值. 相似文献
56.
Dual‐Targeting Nanovesicles for In Situ Intracellular Imaging of and Discrimination between Wild‐type and Mutant p53 下载免费PDF全文
Ruocan Qian Yue Cao Prof. Yi‐Tao Long 《Angewandte Chemie (International ed. in English)》2016,55(2):719-723
p53 is a tumor‐suppressor protein related to the cell cycle and programmed cell apoptosis. Herein, dual‐targeting nanovesicles are designed for in situ imaging of intracellular wild‐type p53 (WTp53) and mutant p53 (MUp53). Nanovesicle‐encapsulated plasmonic gold nanoparticles (AuNPs) were functionalized with consensus DNA duplexes, and a fluorescein isothiocyanate (FITC)‐marked anti‐MUp53 antibody was conjugated to the nanovesicle surface. After entering the cytoplasm, the released AuNPs aggregated through recognition of WTp53 and the double‐stranded DNA. The color changes of AuNPs were observed using dark‐field microscopy, which showed the intracellular WTp53 distribution. The MUp53 location was detected though the immunological recognition between FITC‐labeled anti‐MUp53 and MUp53. Thus, a one‐step incubation method for the in situ imaging of intracellular WTp53 and MUp53 was obtained; this was used to monitor the p53 level under a drug treatment. 相似文献
57.
Dual inhibition of A2A and MAO-B is an emerging strategy in neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). In this study, atom-based three-dimensional quantitative structure–activity relationship (3D-QSAR) and hologram quantitative structure–activity relationship (HQSAR) models were generated with benzothiazine and deazaxanthine derivatives. Based on activity against A2A and MAO-B, two statistically signi?cant 3D-QSAR models (r2 = 0.96, q2 = 0.76 and r2 = 0.91, q2 = 0.63) and HQSAR models (r2 = 0.93, q2 = 0.68 and r2 = 0.97, q2 = 0.58) were developed. In an activity cliff analysis, structural outliers were identified by calculating the Mahalanobis distance for a pair of compounds with A2A and MAO-B inhibitory activities. The generated 3D-QSAR and HQSAR models, activity cliff analysis, molecular docking and dynamic studies for dual target protein inhibitors provide key structural scaffolds that serve as building blocks in designing drug-like molecules for neurodegenerative diseases. 相似文献
58.
Zhengyang Yang Jiafeng Wang Song Liu Feng Sun Ji Miao En Xu Liang Tao Yuxin Wang Shichao Ai Wenxian Guan 《Particle & Particle Systems Characterization》2019,36(7)
Photothermal therapy (PTT) is an emerging noninvasive and precise localized therapeutic modality; however, it is deeply limited by its poor tumor accumulation, inadequate photothermal conversion efficiency, and the thermoresistance of cancer cells. Aimed at these shortcomings, tumor‐targeting nanoparticles (iRGD‐W18O49‐17AAG) comprising carboxyl‐group‐functionalized W18O49 nanoparticles, integrin‐targeting peptide iRGD, and HSP90‐inhibitor 17AAG are developed. The W18O49 nanoparticles act as excellent PTT carriers and computed tomography (CT) imaging contrast agents. The ring type polypeptide iRGD promotes the accumulation of nanoparticles in the tumour and further penetration into cancer cells. The introduction of 17AAG can inhibit the heat‐shock response and overcome the thermoresistance, thus increasing the curative effect of PTT and reducing the chance of tumor recurrence. The W18O49 nanoparticles can also be used to monitor and guide the phototherapeutic through CT and near‐infrared fluorescence imaging after modification with Cy5.5. In addition, superior biosafety is also indicated in both preliminary in vitro and in vivo assessments. The potential of iRGD‐W18O49‐17AAG in tumor targeting, dual modality imaging‐guided and remarkable enhanced PTT of gastric cancer with ignorable side effect both in vitro and in vivo, which may be further applied in clinic, is highlighted. 相似文献
59.
WANG Shihui LI Haiyan WANG Yue GAO Yang YU Shanshan ZHAO Qianqian JIN Xiangqun LU Haibin 《高等学校化学研究》2018,34(2):221-228
In this paper, we synthesized a series of proteolysis targeting chimeras(PROTACs) using VHL E3 ligase ligands for BRD4 protein degradation. One of the most promising compound 19g exhibited robust potency of BRD4 inhibition with IC50 value of (18.6±1.3) nmol/L, respectively. Furthermore, compound 19g potently inhibited cell proliferation in BRD4-sensitive cell lines RS4;11 with IC50 value of (34.2±4.3) nmol/L and capable of inducing degradation of BRD4 protein at 0.4—0.6 µmol/L in the RS4;11 leukemia cells. These data show that compound 19g is a highly potent and efficacious BRD4 degrader. 相似文献
60.
Multifunctional Small Molecule Fluorophore for Long‐Duration Tumor‐Targeted Monitoring and Dual Modal Phototherapy 下载免费PDF全文
Yi Ma Min Zhang Ping Li Zhihao Han Liming Wu Tingting Li Zhaohui Wang Weidong Gao Tao Deng Yueqing Gu 《Particle & Particle Systems Characterization》2017,34(7)
In this work, a specific tumor‐targeted small molecular fluorophore for synchronous long‐duration cancer imaging, photodynamic therapy, and photothermal therapy is synthesized. This novel fluorophore exhibits specific targeting ability in certain tumors (U87MG, MDA‐MB‐231, A549, etc.) based on its inherent structure and efficiently generates local hyperthermia and reactive oxygen species simultaneously for imaging‐guided precise cancer therapy combining the photothermic and photodynamic effects under laser irradiation. Meanwhile, compared to traditional near infrared fluorophore, this novel fluorophore with significantly enhanced stability against photobleaching can prolong the time of tumor imaging and improve the phototherapy efficiency. This work presents a potential strategy to develop small‐molecule‐based cancer theranostic agents for simultaneous cancer targeting, imaging, and therapy. 相似文献